Correlation Between Clal Biotechnology and Lineage Cell

Can any of the company-specific risk be diversified away by investing in both Clal Biotechnology and Lineage Cell at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Clal Biotechnology and Lineage Cell into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Clal Biotechnology Industries and Lineage Cell Therapeutics, you can compare the effects of market volatilities on Clal Biotechnology and Lineage Cell and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Clal Biotechnology with a short position of Lineage Cell. Check out your portfolio center. Please also check ongoing floating volatility patterns of Clal Biotechnology and Lineage Cell.

Diversification Opportunities for Clal Biotechnology and Lineage Cell

0.45

Correlation Coefficient

Clal Biotechnology  Lineage Cell

Very weak diversification

The 3 months correlation between Clal and Lineage is 0.45. Overlapping area represents the amount of risk that can be diversified away by holding Clal Biotechnology Industries and Lineage Cell Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lineage Cell Therapeutics and Clal Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Clal Biotechnology Industries are associated (or correlated) with Lineage Cell. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lineage Cell Therapeutics has no effect on the direction of Clal Biotechnology i.e., Clal Biotechnology and Lineage Cell go up and down completely randomly.

Pair Corralation between Clal Biotechnology and Lineage Cell

Assuming the 90 days trading horizon Clal Biotechnology Industries is expected to generate 0.48 times more return on investment than Lineage Cell. However, Clal Biotechnology Industries is 2.09 times less risky than Lineage Cell. It trades about -0.07 of its potential returns per unit of risk. Lineage Cell Therapeutics is currently generating about -0.14 per unit of risk. If you would invest  3,940  in Clal Biotechnology Industries on September 14, 2024 and sell it today you would lose (420.00) from holding Clal Biotechnology Industries or give up 10.66% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	97.87%
Values	Daily Returns

Clal Biotechnology Industries  vs.  Lineage Cell Therapeutics

Clal Biotechnology

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Clal Biotechnology Industries has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's forward indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Lineage Cell Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Lineage Cell Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Clal Biotechnology and Lineage Cell

The main advantage of trading using opposite Clal Biotechnology and Lineage Cell positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Clal Biotechnology position performs unexpectedly, Lineage Cell can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lineage Cell will offset losses from the drop in Lineage Cell's long position.

The idea behind Clal Biotechnology Industries and Lineage Cell Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.